David Eichenbaum, MD
OSN_EF398_Eichenbaum_Video1
OSN_EF398_Eichenbaum_Video2
OSN_EF398_Eichenbaum_Video3
OSN_EF398_Eichenbaum_Video4
OSN_EF398_Eichenbaum_Video5
OSN_EF398_Eichenbaum_Video6
In an interview, David Eichenbaum, MD, director of research at Retina Vitreous Associates of Florida, discussed:
- how he approaches managing DME treatment, and how best to educate patients on how to be aware of DME;
- how he coordinates with other providers when treating DME, and his process for keeping all parties properly informed;
- the latest on emerging treatments in DME, specifically the widespread use of faricimab (Vabysmo, Genentech);
- how implicit bias, both racial and gender-based, impacts the treatment and diagnosis of DME;
- important areas of unmet need in DME, especially the need for greater patient education;
- and how the COVID-19 pandemic changed DME treatment, and how treatment has further shifted as patients return to doctor's offices in person.
Read more about